Mohamad Mohty

Inserm (FR)

Research Areas

Discover Papers by Mohamad Mohty

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

126

Publications

2122

Citations

62299

i10-index

859

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
Ruxolitinib for Glucocorticoid-Refractory Acute Gr...	2020	816
Acute lymphoblastic leukaemia	2020	696
Oral Selinexor–Dexamethasone for Triple-Class Refr...	2019	655
Mechanisms of action of antithymocyte globulin: T-...	2007	588
Bortezomib Plus Dexamethasone Is Superior to Vincr...	2010	528
Prophylaxis and management of graft versus host di...	2020	523
Revised diagnosis and severity criteria for sinuso...	2016	511
Elranatamab in relapsed or refractory multiple mye...	2023	490
Adoptive transfer of pp65-specific T cells for the...	2010	429
One million haemopoietic stem-cell transplants: a ...	2015	426

Publications

1.
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Year: 2020Citations: 816DOI: 10.1056/nejmoa1917635
2.
Acute lymphoblastic leukaemia
Year: 2020Citations: 696DOI: 10.1016/s0140-6736(19)33018-1
3.
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
Year: 2019Citations: 655DOI: 10.1056/nejmoa1903455
4.
Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond
Year: 2007Citations: 588DOI: 10.1038/sj.leu.2404683
5.
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Year: 2010Citations: 528DOI: 10.1200/jco.2009.27.9158
6.
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Year: 2020Citations: 523DOI: 10.1016/s2352-3026(19)30256-x
7.
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
Year: 2016Citations: 511DOI: 10.1038/bmt.2016.130
8.
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Year: 2023Citations: 490DOI: 10.1038/s41591-023-02528-9
9.
Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation
Year: 2010Citations: 429DOI: 10.1182/blood-2010-01-262089
10.
One million haemopoietic stem-cell transplants: a retrospective observational study
Year: 2015Citations: 426DOI: 10.1016/s2352-3026(15)00028-9

About Mohamad Mohty

Mohamad Mohty is a researcher with 2122 publications and 62299 citations. They are affiliated with Inserm. Their research focuses on . With an h-index of 126, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Mohamad Mohty and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year